One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
PetIQ logo
PetIQ PETQ
report update icon

Quarterly report 2024-Q2
added 07-04-2026

PetIQ Financial Statements 2023-2011 | PETQ

Annual Financial Statements PetIQ

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

396 B 397 B 641 B 947 B 567 B 404 B 289 B - - - - - -

Shares

29.1 B 29.2 B 28.2 B 24.6 B 22.7 B 17.2 B 13.2 B - - - - - -

Historical Prices

13.6 13.6 22.7 38.5 25.1 23.5 21.8 - - - - - -

Net Income

2.13 M -48.2 M -16 M -82.7 M -11.5 M -782 K -3.49 M -3.4 M - - - - -

Revenue

1.1 B 922 M 933 M 780 M 709 M 529 M 267 M 200 M 206 M - - - -

Cost of Revenue

849 M 712 M 746 M 645 M 602 M 445 M 215 M 168 M - - - - -

Gross Profit

253 M 210 M 186 M 135 M 107 M 83.3 M 51.2 M 32.5 M 39.2 M - - - -

Operating Income

37.1 M -20.2 M 15.9 M -3.19 M -3.14 M 7.75 M 13.3 M 702 K 3.57 M - - - -

Interest Expense

38.3 M 28.2 M 24.7 M 22.8 M 14.9 M 8.3 M 1.56 M 3.1 M 3.57 M - - - -

EBITDA

81.6 M 15.3 M 55.2 M 24.3 M 13.4 M 20.2 M 16.9 M 4.78 M 6.71 M - - - -

Operating Expenses

- - - 138 M 103 M 72.3 M 37.9 M 31.8 M 35.6 M - - - -

General and Administrative Expenses

196 M 183 M 171 M 138 M 103 M 72.3 M 37.9 M 31.8 M 35.6 M - - - -

All numbers in USD currency

Quarterly Income Statement PetIQ

2024-Q2 2024-Q1 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

29.5 M 29.3 M 29.2 M 29.1 M 29.1 M - 29.2 M 29.3 M 29.2 M 29.1 M 28.9 M 28.5 M 26.4 M 25.7 M 24.9 M 24.4 M 23.7 M 23.4 M 23 M 22.4 M 21.8 M 21.3 M 16.9 M 16 M 14.6 M 13.2 M 13.2 M 13.2 M 13.2 M - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

15.3 M 14.9 M 451 K 9.47 M 9.7 M - -49.1 M 4.63 M 3.13 M - -7.9 M 4.03 M 2.03 M - -63.1 M -1.89 M -2.1 M -13.8 M -5.89 M 3.82 M 1.61 M -5.26 M 2.22 M 2.5 M -2.03 M -3.39 M -226 K 6.07 M 4.28 M -1.18 M -2.51 M 598 K -304 K - - - - - - - - - - - - - - - - - - - -

Revenue

329 M 308 M 277 M 315 M 290 M - 210 M 252 M 276 M - 211 M 271 M 254 M - 162 M 267 M 187 M - 186 M 221 M 148 M 16.9 M 131 M 171 M 115 M 51.9 M 60.6 M 87.2 M 67 M 44.9 M 41.7 M 61.3 M 52.3 M - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

241 M 234 M 204 M 241 M 228 M - 159 M 190 M 218 M - 168 M 211 M 207 M - 130 M 225 M 155 M - 159 M 186 M 124 M - 107 M 145 M 99.2 M - 48 M 71.2 M 54.8 M - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

88.3 M 74.5 M 72.6 M 73.9 M 62.3 M - 50.8 M 62 M 57.6 M - 42.1 M 59.6 M 47.8 M - 32.3 M 42.2 M 32.2 M 20.5 M 27.3 M 34.9 M 24.7 M 16.9 M 24.2 M 26.3 M 15.9 M 10.5 M 12.5 M 16 M 12.2 M 7.65 M 6.16 M 8.96 M 9.77 M - - - - - - - - - - - - - - - - - - - -

Operating Income

25.6 M 24.3 M 9.36 M 18.7 M 18.9 M - -42.5 M 11.4 M 9.4 M - -3.18 M 16.5 M 7.13 M - -3.29 M 3.69 M 464 K -12.6 M -4.36 M 8.99 M 4.87 M -4.85 M 6.56 M 9.38 M -3.08 M 42 K 1.78 M 6.67 M 4.8 M 116 K -1.78 M 659 K 1.71 M - - - - - - - - - - - - - - - - - - - -

Interest Expense

-9.25 M -9.11 M -8.58 M -8.82 M -8.73 M - -7.28 M -6.3 M -6.12 M - -6.17 M -7.66 M -4.87 M - 7.83 M 5.97 M 4.7 M - 5.74 M -2.24 M -1.94 M - -2.16 M -2.22 M -1.94 M - 352 K -535 K -516 K - 737 K - - - - - - - - - - - - - - - - - - - - - -

EBITDA

41.4 M 32.7 M 45.2 M 38.5 M 27.4 M - -15.9 M 29 M 18.4 M - 25.8 M 36.9 M 19.5 M - 17.6 M 15.5 M 5.93 M -12.6 M 6.64 M 15 M 7.96 M -4.85 M 15.5 M 15.1 M -563 K 42 K 4.5 M 8.36 M 5.65 M 116 K 1.1 M 659 K 1.71 M - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

60.1 M 50.2 M 55 M 55.2 M 43.3 M - 46 M 50.6 M 48.2 M - 45.3 M 43.1 M 40.7 M - 35.6 M 38.5 M 31.7 M 28.9 M 29.3 M 24.4 M 20.5 M 18.7 M 17.6 M 16.9 M 19 M 10.5 M 10.7 M 9.28 M 7.4 M 7.54 M 7.94 M 8.3 M 8.06 M - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements PetIQ PETQ
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting PetIQ plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Drug manufacturers industry

Issuer Price % 24h Market Cap Country
Perrigo Company plc Perrigo Company plc
PRGO
$ 15.79 -1.16 % $ 2.19 B usaUSA
Tricida Tricida
TCDA
- - $ 3.25 M usaUSA
Avadel Pharmaceuticals plc Avadel Pharmaceuticals plc
AVDL
- - $ 2.06 B franceFrance
DURECT Corporation DURECT Corporation
DRRX
- - $ 50.1 M usaUSA
Bausch Health Companies Bausch Health Companies
BHC
$ 6.35 -1.55 % $ 2.36 B canadaCanada
Athenex Athenex
ATNX
- -23.39 % $ 1.76 M usaUSA
Endo International plc Endo International plc
ENDP
- - $ 28.9 M irlandaIrlanda
Aerie Pharmaceuticals Aerie Pharmaceuticals
AERI
- - $ 754 M usaUSA
Radius Health Radius Health
RDUS
- - $ 1.42 B usaUSA
Recro Pharma Recro Pharma
REPH
- -4.76 % $ 65.3 M usaUSA
Agile Therapeutics Agile Therapeutics
AGRX
- 10.11 % $ 58.2 M usaUSA
Adamis Pharmaceuticals Corporation Adamis Pharmaceuticals Corporation
ADMP
- 0.86 % $ 117 M usaUSA
Evoke Pharma Evoke Pharma
EVOK
- - $ 36.6 M usaUSA
Cumberland Pharmaceuticals Cumberland Pharmaceuticals
CPIX
$ 5.14 -39.46 % $ 76.4 M usaUSA
Cronos Group Cronos Group
CRON
$ 3.33 -0.6 % $ 1.28 B canadaCanada
Alimera Sciences Alimera Sciences
ALIM
- - $ 142 M usaUSA
Emergent BioSolutions Emergent BioSolutions
EBS
$ 6.37 2.25 % $ 341 M usaUSA
Evolus Evolus
EOLS
$ 7.15 2.0 % $ 461 M usaUSA
PLx Pharma PLx Pharma
PLXP
- -27.8 % $ 2.56 M usaUSA
Lannett Company Lannett Company
LCI
- 1.15 % $ 7.11 M usaUSA
Zynerba Pharmaceuticals Zynerba Pharmaceuticals
ZYNE
- - $ 55.5 M usaUSA
Catalent Catalent
CTLT
- - $ 11.5 B usaUSA
Eagle Pharmaceuticals Eagle Pharmaceuticals
EGRX
- -39.89 % $ 27.7 M usaUSA
OptiNose OptiNose
OPTN
- - $ 1.08 B usaUSA
Aurora Cannabis Aurora Cannabis
ACB
$ 3.93 1.16 % $ 215 M canadaCanada
Harrow Health Harrow Health
HROW
$ 28.67 0.81 % $ 1.05 B usaUSA
Canopy Growth Corporation Canopy Growth Corporation
CGC
$ 0.67 -1.41 % $ 200 M canadaCanada
Organogenesis Holdings Organogenesis Holdings
ORGO
$ 0.96 -3.58 % $ 122 M usaUSA
SCYNEXIS SCYNEXIS
SCYX
$ 3.87 2.27 % $ 193 M usaUSA
Solid Biosciences Solid Biosciences
SLDB
$ 5.8 -2.03 % $ 508 M usaUSA
Sundial Growers Sundial Growers
SNDL
$ 1.25 -3.1 % $ 323 M canadaCanada
Sonoma Pharmaceuticals Sonoma Pharmaceuticals
SNOA
$ 1.12 0.9 % $ 1.89 M usaUSA
Tilray Tilray
TLRY
$ 2.7 -3.91 % $ 302 M canadaCanada
TherapeuticsMD TherapeuticsMD
TXMD
$ 1.81 0.56 % $ 20.9 M usaUSA
Pacira BioSciences Pacira BioSciences
PCRX
$ 36.4 -0.05 % $ 1.62 B usaUSA
Veru Veru
VERU
$ 2.21 -1.34 % $ 32.4 M usaUSA
Viatris Viatris
VTRS
$ 18.32 1.76 % $ 21 B usaUSA
Rockwell Medical Rockwell Medical
RMTI
$ 6.93 -0.09 % $ 249 M usaUSA
OrganiGram Holdings OrganiGram Holdings
OGI
$ 0.93 0.92 % $ 88.6 M canadaCanada
China Pharma Holdings China Pharma Holdings
CPHI
$ 0.63 -2.4 % $ 2.7 M chinaChina
Relmada Therapeutics Relmada Therapeutics
RLMD
$ 3.26 -0.31 % $ 129 M usaUSA
cbdMD cbdMD
YCBD
$ 0.37 1.16 % $ 1.49 M usaUSA
HEXO Corp. HEXO Corp.
HEXO
- 2.45 % $ 38.1 M canadaCanada
Calliditas Therapeutics AB (publ) Calliditas Therapeutics AB (publ)
CALT
- -0.1 % $ 2.03 B schwedenSchweden
AcelRx Pharmaceuticals AcelRx Pharmaceuticals
ACRX
- 7.5 % $ 6.35 M usaUSA
Assertio Holdings Assertio Holdings
ASRT
- - $ 150 M usaUSA
Jupiter Wellness Jupiter Wellness
JUPW
- - $ 33.6 M usaUSA
Neoleukin Therapeutics Neoleukin Therapeutics
NLTX
- - $ 193 M canadaCanada
ProPhase Labs ProPhase Labs
PRPH
- - $ 5.07 M usaUSA